Key Takeaways RVTY Q2 sales rose 4.1% to $720.3M, topping estimates; adjusted EPS beat by 3.5$1.18.RVTY's Diagnostics grew 3% and Life Sciences rose 4% organically, despite margin contraction.RVTY raised 2025 revenue guidance to $2.84-$2.88B but lowered EPS outlook to $4.85-$4.95.Revvity, Inc. (RVTY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.18, which beat the Zacks Consensus Estimate of$1.14 by 3.5%. The bottom line, however, declined 3.3% from the year-ago quarter’s level. ...